[go: up one dir, main page]

MX2018004406A - Anticuerpo monoclonal bactericida contra la klebsiella pneumoniae. - Google Patents

Anticuerpo monoclonal bactericida contra la klebsiella pneumoniae.

Info

Publication number
MX2018004406A
MX2018004406A MX2018004406A MX2018004406A MX2018004406A MX 2018004406 A MX2018004406 A MX 2018004406A MX 2018004406 A MX2018004406 A MX 2018004406A MX 2018004406 A MX2018004406 A MX 2018004406A MX 2018004406 A MX2018004406 A MX 2018004406A
Authority
MX
Mexico
Prior art keywords
klebsiella pneumoniae
monoclonal antibody
antibody targeting
bactericidal
bactericidal monoclonal
Prior art date
Application number
MX2018004406A
Other languages
English (en)
Inventor
Mirkina Irina
Nagy Estzer
Nagy Gábor
Szijarto Valeria
Miguel Guachalla Luis
Visram Zehra
Original Assignee
Arsanis Biosciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arsanis Biosciences Gmbh filed Critical Arsanis Biosciences Gmbh
Publication of MX2018004406A publication Critical patent/MX2018004406A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • G01N33/56916Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/26Klebsiella (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)

Abstract

Un anticuerpo IgG monoclonal bactericida humano o humanizado que reconoce específicamente el antígeno D-galactán-II de la Klebsiella pneumoniae O1 el cual se caracteriza por una actividad de CDC bactericida, su método de producción, uso médico y diagnóstico.
MX2018004406A 2015-10-16 2016-10-14 Anticuerpo monoclonal bactericida contra la klebsiella pneumoniae. MX2018004406A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15190136 2015-10-16
PCT/EP2016/074728 WO2017064258A1 (en) 2015-10-16 2016-10-14 Bactericidal monoclonal antibody targeting klebsiella pneumoniae

Publications (1)

Publication Number Publication Date
MX2018004406A true MX2018004406A (es) 2019-07-01

Family

ID=54359802

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004406A MX2018004406A (es) 2015-10-16 2016-10-14 Anticuerpo monoclonal bactericida contra la klebsiella pneumoniae.

Country Status (13)

Country Link
US (1) US20180298084A1 (es)
EP (1) EP3362474A1 (es)
JP (1) JP2018533938A (es)
KR (1) KR20180084793A (es)
CN (1) CN108602880A (es)
AU (1) AU2016336901A1 (es)
BR (1) BR112018007483A2 (es)
CA (1) CA3000901A1 (es)
IL (1) IL258475A (es)
MX (1) MX2018004406A (es)
RU (1) RU2018117651A (es)
WO (1) WO2017064258A1 (es)
ZA (1) ZA201802136B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11447542B2 (en) 2016-08-05 2022-09-20 Medimmune, Llc Anti-O2 antibodies and uses thereof
KR20190064636A (ko) 2016-10-19 2019-06-10 메디뮨 엘엘씨 항-o1 항체 및 이의 용도
KR102581500B1 (ko) * 2021-01-20 2023-09-20 서울대학교산학협력단 폐렴간균 독소-항독소 시스템을 표적으로 하는 항균 펩타이드 및 화합물, 및 이들의 용도
KR102657660B1 (ko) * 2021-06-15 2024-04-15 경상국립대학교산학협력단 폐렴간균 검출용 신규한 펩타이드
WO2023025173A1 (zh) * 2021-08-25 2023-03-02 舒泰神(北京)生物制药股份有限公司 特异性识别肺炎克雷伯菌o1抗原的抗体及其应用
IT202300000924U1 (it) * 2023-01-23 2024-12-22 Philomena Dove Cucitura all-up leggins seamless

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
CA2625183C (en) * 2005-10-04 2019-09-03 Inimex Pharmaceuticals Inc. Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
CA3187687A1 (en) 2007-09-14 2009-03-19 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3336225B1 (en) 2010-07-16 2020-02-19 Adimab, LLC Antibody libraries
WO2012146630A1 (en) * 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
US20150197558A1 (en) * 2013-09-26 2015-07-16 Trellis Bioscience, Llc Binding moieties for biofilm remediation

Also Published As

Publication number Publication date
RU2018117651A (ru) 2019-11-20
CN108602880A (zh) 2018-09-28
EP3362474A1 (en) 2018-08-22
ZA201802136B (en) 2019-09-25
IL258475A (en) 2018-05-31
CA3000901A1 (en) 2017-04-20
KR20180084793A (ko) 2018-07-25
BR112018007483A2 (pt) 2018-10-23
AU2016336901A1 (en) 2018-05-10
US20180298084A1 (en) 2018-10-18
WO2017064258A1 (en) 2017-04-20
JP2018533938A (ja) 2018-11-22

Similar Documents

Publication Publication Date Title
MX2018004406A (es) Anticuerpo monoclonal bactericida contra la klebsiella pneumoniae.
MY184154A (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
EP3689909A4 (en) Tigit antibody, antigen-binding fragment thereof, and medical use thereof
PH12018501554A1 (en) Ror1 antibody compositions and related methods
MX2021005396A (es) Anticuerpo anti-cd73, fragmento de union a antigeno y aplicacion del mismo.
PH12017500819A1 (en) Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production
TN2016000559A1 (en) Monoclonal antibodies against her2 epitope and methods of use thereof
IL281272A (en) Humanized antibodies against C5 and their uses
JOP20170004B1 (ar) الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
MX2018011633A (es) Diagnostico no invasivo de esteatohepatitis no alcoholica.
EP4249515A3 (en) Humanized or chimeric cd3 antibodies
MX2017005987A (es) Anticuerpos anti-interleucina(il)-1beta y metodos de uso.
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
MA39821A (fr) Molécules de liaison spécifiques de l'il-21 et leurs utilisations
EP3778636A4 (en) ANTI-CD27 ANTIBODIES, ANTIGEN BINDING FRAGMENT AND ASSOCIATED MEDICAL USE
IL274951A (en) Human antibodies directed against human tissue factor
MX2014010987A (es) Tratamiento de esclerosis multiple con anticuerpo anti-cd19.
MX2019015914A (es) Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide.
EA201892313A1 (ru) Гуманизированные антитела против clever-1 и их применение
PH12019500434A1 (en) Anti-gm-csf antibodies and uses thereof
MX2018012061A (es) Inhibidor monovalente de la interaccion hutnfr1.
EP3524624A4 (en) ANTI-CD27 ANTIBODIES, ANTIGEN-BINDING FRAGMENT THEREOF, AND ITS MEDICAL USE
IL269655B1 (en) An erbb-2-targeted agent and a bispecific antibody with antigen-binding sites that bind epitopes on the extracellular part of erbb-2 and erbb-3, for the treatment of individuals with erbb-2, erbb-2/erbb-3 positive cancer tumors
PH12021550991A1 (en) Monoclonal antibody that specifically binds to cd20